We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

70 hedge funds and large institutions have $95.8M invested in Spyre Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

3% more funds holding

Funds holding: 68 → 70 (+2)

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

0.02% less ownership

Funds ownership: 2.85% → 2.83% (-0.02%)

39% less capital invested

Capital invested by funds: $158M → $95.8M (-$62M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
70
Holders Change
+2
Holders Change %
+2.94%
% of All Funds
1.54%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
9
Increased
23
Reduced
22
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$680K
2
SCM
Soleus Capital Management
Connecticut
+$533K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$271K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$185K
5
Renaissance Technologies
Renaissance Technologies
New York
+$162K

Top Sellers

Rank Fund Capital Flow
1
Russell Investments Group
Russell Investments Group
United Kingdom
-$611K
2
PAWC
P.A.W. Capital
Connecticut
-$415K
3
Man Group
Man Group
United Kingdom
-$315K
4
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$303K
5
Morgan Stanley
Morgan Stanley
New York
-$222K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$13.4M – – –
NCM
2
Nantahala Capital Management
Connecticut
$13.1M – – –
BlackRock
3
BlackRock
New York
$8.9M -$90.1K -530 -0.7%
BBA
4
Baker Bros. Advisors
New York
$7.99M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$6.84M – – –
ACM
6
Aisling Capital Management
New York
$6.02M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$5.52M +$28.1K +165 +0.3%
Marshall Wace
8
Marshall Wace
United Kingdom
$3.91M +$39.1K +230 +0.7%
RSCM
9
Rock Springs Capital Management
Maryland
$3.73M – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$2.79M +$162K +950 +4%
SCM
11
Soleus Capital Management
Connecticut
$2.5M +$533K +3,133 +17%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$2.46M -$19.2K -113 -0.5%
State Street
13
State Street
Massachusetts
$2.2M +$46.9K +276 +1%
Goldman Sachs
14
Goldman Sachs
New York
$1.97M -$139K -819 -5%
AG
15
Artal Group
Luxembourg
$1.86M +$680K +4,000 +33%
UOTTAIMCU
16
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$1.5M – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.49M +$40.1K +236 +2%
Northern Trust
18
Northern Trust
Illinois
$1.38M +$17.3K +102 +0.9%
A
19
Abingworth
United Kingdom
$1.1M – – –
RWM
20
Ritholtz Wealth Management
New York
$1.05M -$136K -800 -8%
BCM
21
Bridgeway Capital Management
Texas
$534K +$81.6K +480 +12%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$443K +$32.3K +190 +5%
N
23
Nuveen
North Carolina
$413K -$2.38K -14 -0.4%
Wells Fargo
24
Wells Fargo
California
$319K +$86.9K +511 +23%
Russell Investments Group
25
Russell Investments Group
United Kingdom
$290K -$611K -3,594 -59%
1
2 3 4

SYRE Hedge Fund Activity: Q1 2020 in Review

70 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2020, worth a combined $95.8M — down 39% from $158M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SYRE positions and 6 closed out — a net gain of 3 holders — while 23 added to existing stakes and 22 trimmed.

The largest buyer was Artal Group, adding an estimated $680K. The largest seller was Russell Investments Group, cutting an estimated $611K.

  • 70 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2020, up from 68 in Q4 2019.
  • Funds reported $95.8M of Spyre Therapeutics stock for Q1 2020, down 39% quarter-over-quarter.
  • 9 funds opened new Spyre Therapeutics positions in Q1 2020 and 6 closed out, a net change of +3 holders.
  • The largest Spyre Therapeutics buyer in Q1 2020 was Artal Group, an estimated $680K added.
  • The largest Spyre Therapeutics seller in Q1 2020 was Russell Investments Group, an estimated $611K sold.

Based on aggregated 13F filings for Q1 2020.